Figure 1: Tissue distribution of fenofibrate in animals following fenofibrate treatment. (A) A representative HPLC-MS spectrum of fenofibrate (20 ng/μl; m/z 361.1 ± 0.3) in the retina. (B) A representative HPLC-MS spectrum of the extracted ion chromatogram of fenofibric acid (F.A.) and fenofibrate (F); BZFA (I.S.) served as an internal standard. (C-E) Normal Brown Norway adult rats were topically administered fenofibrate eyedrops (15 μl/eye). (C) A representative HPLC-MS spectrum of the extracted ion chromatogram of fenofibric acid (F.A.), and fenofibrate (F) from eyecup extracts at 0, 1 h, 2 h, 3 h, 4 h, 5 h and 6 h, respectively. (D,E) Fenofibrate or fenofibric acid levels in eyecup and retinal extracts at 0, 1 h, 2 h, 3 h, 4 hr, 5 h, 6 h, 12 h, 24 h, and 48 h were determined using HPLC/MS (mean ± SD, n =3). (F) Normal adult rats were fed fenofibrate (0.06% or 0.2%) for 5 days, and fenofibric acid levels in the serum, retina, and liver extracts were determined using HPLC/MS (mean ± SD, n =3). (G) Normal adult rats were treated with oral fenofibrate (120 mg/kg/d, 5 days). Fenofibrate or fenofibric acid levels in tissue extracts were determined using HPLC-MS in animals administered oral fenofibrate and in animals administered topical fenofibrate eyedrops (4 times/day, 5 days) (mean ± SD, n=5).